Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

被引:0
|
作者
N Echeverry
G Ziltener
D Barbone
W Weder
R A Stahel
V C Broaddus
E Felley-Bosco
机构
[1] Laboratory of Molecular Oncology,Department of Medicine, Division of Pulmonary
[2] Clinic of Oncology,Division of Thoracic Surgery
[3] University Hospital of Zürich,undefined
[4] San Francisco General Hospital,undefined
[5] University of California San Francisco,undefined
[6] University Hospital Zürich,undefined
来源
Cell Death & Disease | 2015年 / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Malignant pleural mesothelioma (MPM) originates in most of the cases from chronic inflammation of the mesothelium due to exposure to asbestos fibers. Given the limited effect of chemotherapy, a big effort is being made to find new treatment options. The PI3K/mTOR pathway was reported to be upregulated in MPM. We tested the cell growth inhibition properties of two dual PI3K/mTOR inhibitors NVP-BEZ235 and GDC-0980 on 19 MPM cell lines. We could identify resistant and sensitive lines; however, there was no correlation to the downregulation of PI3K/mTOR activity markers. As a result of mTOR inhibition, both drugs efficiently induced long-term autophagy but not cell death. Autophagy blockade by chloroquine in combination with the dual PI3K/mTOR inhibitors significantly induced caspase-independent cell death involving RIP1 in the sensitive cell line SPC212. Cell death in the resistant cell line Mero-82 was less pronounced, and it was not induced via RIP1-dependent mechanism, suggesting the involvement of RIP1 downstream effectors. Cell death induction was confirmed in 3D systems. Based on these results, we identify autophagy as one of the main mechanisms of cell death resistance against dual PI3K/mTOR inhibitors in MPM. As PI3K/mTOR inhibitors are under investigation in clinical trials, these results may help interpreting their outcome and suggest ways for intervention.
引用
收藏
页码:e1757 / e1757
相关论文
共 50 条
  • [1] Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
    Echeverry, N.
    Ziltener, G.
    Barbone, D.
    Weder, W.
    Stahel, R. A.
    Broaddus, V. C.
    Felley-Bosco, E.
    CELL DEATH & DISEASE, 2015, 6 : e1757 - e1757
  • [2] MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
    Kanteti, Rajani
    Dhanasingh, Immanuel
    Kawada, Ichiro
    Lennon, Frances E.
    Arif, Qudsia
    Bueno, Raphael
    Hasina, Rifat
    Husain, Aliya N.
    Vigneswaran, Wickii
    Seiwert, Tanguy
    Kindler, Hedy L.
    Salgia, Ravi
    PLOS ONE, 2014, 9 (09):
  • [3] Met and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
    Kanteti, Rajani
    Riehm, Jacob J.
    Lennon, Frances
    Vigneswaran, Wickii T.
    Hasina, Rifat
    Kindler, Hedy Lee
    Salgia, Ravi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S503 - S503
  • [4] Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
    Miyoshi, Seigo
    Hamada, Hironobu
    Hamaguchi, Naohiko
    Kato, Aki
    Katayama, Hitoshi
    Irifune, Kazunori
    Ito, Ryoji
    Miyazaki, Tatsuhiko
    Okura, Takafumi
    Higaki, Jitsuo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (02) : 449 - 456
  • [5] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [6] Design and synthesis of dual PI3K/mTor inhibitors
    Olivero, Alan
    Heffron, Timothy
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Chang, Christine
    Dotson, Jennafer
    Friedman, Lori
    Goldsmith, Richard
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Pang, Jodie
    Peterson, David
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Daniel
    Tsui, Vickie
    Ultsch, Mark
    Wang, Shumei
    Wiesmann, Christian
    Wong, Susan
    Zhu, Bing-Yan
    Chuckowree, Irina
    Folkes, Adrian
    Shuttleworth, Steve
    CANCER RESEARCH, 2009, 69
  • [7] Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models
    Powley, Ian
    Galavotti, Sara
    Sun, Xiao-Ming
    Chernova, Tatyana
    Nakas, Apostolos
    Le Quesne, John
    Pringle, Howard
    Fennell, Dean
    MacFarlane, Marion
    TOXICOLOGY LETTERS, 2014, 229 : S153 - S153
  • [8] Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
    Husu, E. N.
    Roccaro, A. M.
    Anderson, K. C.
    Ghobrial, I. M.
    Leleu, X.
    Sacco, A.
    Melhem, M. R.
    Azab, A. K.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Runnels, J.
    Quang, P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S144 - S145
  • [9] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [10] DEPLETION OF CLK2 SENSITIZES GLIOMA CELLS TO PI3K/mTOR AND FGFR INHIBITION
    Park, Soon Young
    Dong, Jianwen
    Martinez-Ledesma, Emmanuel
    Piao, Yuji
    Verhaak, Roel G. W.
    de Groot, John F.
    NEURO-ONCOLOGY, 2016, 18 : 44 - 44